-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 17, Xinhua Pharmaceutical announced that its wholly-owned subsidiary Shandong Zibo Xinda Pharmaceutical Co.
, Ltd.
("Xinda Pharmaceutical") received the "Approval Notice for Supplementary Drug Application" for pioglitazone hydrochloride capsules approved and issued by the State Food and Drug Administration.
, the product consistency evaluation application was approved
.
Xinda Pharmaceutical is the first company in China to pass the consistency evaluation of pioglitazone hydrochloride capsules
.
Pioglitazone hydrochloride was developed by Takeda Corporation of Japan.
It was first listed in the United States in July 1999.
It is mainly used for the treatment of type 2 diabetes.
It has been listed in Australia, Canada, Japan, Germany, Denmark, Spain and other countries and is widely used
.
Relevant data show that in the past three years, the sales of pioglitazone hydrochloride tablets in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) have remained above 500 million yuan